Form 4: Lilly Endowment Inc. Sells Over 100,000 Shares of Eli Lilly & Co. in Multiple Transactions

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold over 100,000 shares of common stock in a series of transactions on February 16, 2024.

Summary

• Lilly Endowment Inc. sold a total of 138,810 shares of Eli Lilly & Co. common stock on February 16, 2024.
• The sales were executed in multiple transactions throughout the day.
• The prices per share ranged from $763.68 to $793.245.
• The weighted average prices for each block of sales are detailed in the document.
• Following these transactions, Lilly Endowment Inc. still holds a substantial 98,898,810 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock sales, with no indication of positive or negative sentiment.

Risks

• Large sales by major shareholders can sometimes create downward pressure on a stock's price.

Industry Context

This filing is a routine disclosure of stock transactions by a major shareholder and is common in the pharmaceutical industry.

Comparison to Industry Standards

• Large institutional investors like Lilly Endowment Inc. often adjust their holdings in response to market conditions or portfolio strategies.
• These types of transactions are common and are regularly disclosed via SEC filings.
• Other major shareholders in pharmaceutical companies also make similar transactions, and these are often monitored by investors.

Stakeholder Impact

• The sale of shares by a major shareholder could have a minor impact on the stock price, but the overall impact is likely to be minimal given the large number of shares still held by Lilly Endowment Inc.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, SEC Form 4